Hypera stock
Price history
−13.99% over the period1 year: from R$25.31 (November 24, 2025) to R$21.77 (November 22, 2026), −13.99%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 22, 2026 | R$21.77 |
| October 30, 2026 | R$21.27 |
| September 30, 2026 | R$24.48 |
| August 31, 2026 | R$21.70 |
| July 31, 2026 | R$21.27 |
| June 30, 2026 | R$20.81 |
| May 29, 2026 | R$21.91 |
| April 30, 2026 | R$22.53 |
| March 31, 2026 | R$23.28 |
| February 27, 2026 | R$23.08 |
| January 30, 2026 | R$25.21 |
| December 30, 2025 | R$23.56 |
| November 28, 2025 | R$26.80 |
| November 24, 2025 | R$25.31 |
At a glance
The company
Pharmaceutical company offering sweeteners, analgesics, cold and flu remedies, antihistamines, antiseptics, herbal medicines, gastrointestinal products, generics, skincare, supplements and vitamins in Brazil
Latest results
Quarter to September 30, 2026 · EPS R$0.75 (estimate R$0.69)
TickerLandia's take on Hypera
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 12 vs a median of 17 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 8.1 vs 17 (−52%) in a group of 10.
- Strong point: Dividend (64/100 in its group). Weak point: Financial strength (21/100).
- “Value traps” (Brazil): No. 4 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−27.43% from the 52-week high
Analysts · 15 analysts
Average targetR$29.40+35.05% vs. price
Buy 14 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Hypera
Compared with similar companies: very low price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 317 Latin American stocks.
Pricevery low8
How much it costs relative to what it produces.
Metric Value Position in group Price/book 1.05 6 EV/EBITDA 7.76 10 Forward P/E 7.34 4 Price/sales 1.71 17 P/E (trailing 12 months) 8.05 1 Profitabilityaverage57
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 61.2% 35 Net margin 20.1% 73 ROE 13.4% 50 ROA 6.2% 47 Operating margin 28.1% 78 Earnings stabilityaverage47
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.2% 30 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthlow36
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +0.67% 14 Revenue growth (year over year) +9.40% 36 Earnings growth (year over year) +3.10% 56 Financial strengthlow21
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 4.03 4 Interest coverage 1.67 6 Debt/equitycounts in reverse: lower means more financial strength 0.53 34 Current ratio 1.73 40 Dividendhigh64
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 11 years 41 Dividend yield 4.8% 95 Payout ratio 39.6% 56 Market momentumaverage52
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average −3.56% 54 Relative strength (3 months) +5.63% 63 Relative strength (6 months) +4.08% 60 1-year return −14.39% 31 Riskhigh64
How much the price swings.
Metric Value Position in group Volatility (60 days) 66.8% 83 Beta (1 year) 1.32 63 Maximum drawdown (12 months) 27.1% 46
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Hypera is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Hypera's P/E today is 11.6, below the median of its last 10 fiscal years (16.7; between 8.59 and 25.9 from 2016 to 2025). Hypera's P/E (trailing 12 months): 8.09, −52% against the median of a group of 10 similar companies (17.0).
Compared with 10 similar companies
| Metric | Hypera | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 8.09 | Low | |
| Forward P/E | 7.29 | Low | |
| Operating margin | 28.1% | High | |
| ROE | 13.4% | Middle | |
| Debt/equity | 0.53 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Hypera. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
R$2.44B
Latest quarter · Q3 2026
Net income
R$523.15M
Latest quarter · Q3 2026
Quarterly net margin
21.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- R$15.33B
- P/E
- 8.1
- EPS
- R$2.69
- Volume
- 3.37M
- Daily trading
- €14.87M
- Dividend yield
- 4.97%
- Last ex-dividend on September 29, 2026
How Hypera is changing
All resultsRevenue grew 13.5% a year on average over the last 5 years
Operating margin fell from 32.3% to 22.7%
Profits turn into cash: free cash flow equal to 145% of net income
Returns
Hypera returns with dividends
R$1,000 invested in Hypera 5 years ago, on November 22, 2021, would be worth R$929 today with dividends reinvested: −7.09% in total, −1.46% per year. On price alone it would be R$758 (−24.17%).
| Period | Hypera | Ibovespa | R$1,000 becomes |
|---|---|---|---|
| 1 month | −17.79% | −18.87% | R$822 |
| 6 months | −3.50% | −5.58% | R$965 |
| Year to date | −7.60% | +3.26% | R$924 |
| 1 year | −9.83% | +7.15% | R$902 |
| 3 years | −27.12% | +32.01% | R$729 |
| 5 years | −7.09% | +62.92% | R$929 |
| 10 years | +22.08% | +168.55% | R$1,221 |
Over the last 6 months it has done better than 25% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Ibovespa: with dividends. Calculate your investment
The chart in detail
Hypera: technical analysis
Hypera shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 57.2% below its all-time closing high (R$50.81, October 31, 2022).
- Trend
- No clear trend
- RSI (14 sessions)
- 41
- Between 30 and 70
- vs 200-session average
- −3.48%
Support and resistance
Price areas where Hypera has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceR$23.74+9.03%4 touches, last on September 29, 2026
- ResistanceR$22.69+4.21%4 touches, last on August 7, 2026
- ResistanceR$21.93+0.72%9 touches, last on September 14, 2026
- Last priceR$21.77
- SupportR$20.50−5.85%3 touches, last on November 3, 2026
- SupportR$19.94−8.42%3 touches, last on July 24, 2026
Volatility and risk
Over the last year it has moved more than the Ibovespa.
- Beta (1 year) vs Ibovespa
- 1.32
- Volatility (60 sessions, annualised)
- 66.4%
- Largest fall in the last year
- −27.09%
In session, November 22, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Hypera: seasonality
Average monthly price change over 19 years
Over the last 19 years, the strongest month for Hypera has been March: +3.71% on average, positive in 13 years out of 18. The weakest has been August: −1.10% on average, positive in 9 years out of 19. November, the current month, has been positive in 8 years out of 18 (+0.71% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.41% | +2.80% | 12 of 18 |
| February | +0.65% | +0.44% | 9 of 18 |
| March | +3.71% | +2.44% | 13 of 18 |
| April | +2.19% | +1.26% | 11 of 18 |
| May | +3.29% | +5.02% | 12 of 19 |
| June | −0.90% | −1.01% | 8 of 19 |
| July | +1.48% | +0.63% | 12 of 19 |
| August | −1.10% | −0.22% | 9 of 19 |
| September | −0.62% | +2.74% | 10 of 19 |
| October | +0.79% | +3.98% | 11 of 19 |
| November | +0.71% | −2.90% | 8 of 18 |
| December | +0.11% | +2.98% | 11 of 18 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Hypera and its competitors
Doril, Buscopan, Neosaldina and Engov are among the brands most people associate with Hypera S.A., a Brazilian drugmaker whose catalogue covers painkillers and anti-inflammatories, cold and flu remedies, antihistamines, digestive products, antiseptics such as Merthiolate, herbal medicines, vitamins, supplements and skincare lines. Its activities are concentrated in Brazil, and the group also sells generics under the neo quimica name as well as sweeteners under Adocyl and Zero-cal, with the Dramin and Cepacol brands rounding out its range.
- Headquarters
- São Paulo, Brazil
- Employees
- 10,564
- Founded
- 1999
- Chief executive
- Breno Pires de Oliveira
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| HyperaHYPE3 | $2.58B | 28.1% | 8.09 | −3.50% |
| Genomma Lab InternacionalLAB/B | $776.89M | 20.0% | 8.71 | −9.05% |
| AlmirallALM | $2.45B | 9.6% | 30.2 | −9.84% |
| Siegfried HoldingSFZN | $3.4B | 16.7% | 16.7 | −19.46% |
| Hims & Hers HealthHIMS | $3.42B | -6.4% | — | −36.63% |
| FagronFAGR | $1.97B | 14.3% | 19.5 | −0.20% |
Same industry or related industries, similar size. Compare Hypera with its competitors · Full profile
